Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs Advances the pharmaceutical drug development programs in… Read More
RADNOR, Pa. — The board of directors of Avantor, Inc. (NYSE: AVTR) a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and… Read More
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort… Read More
News Release | This research study is an important step toward freeing diabetic patients from daily insulin injections and immune suppressing drugs. Researchers from the University of British Columbia (UBC)… Read More
In patients with moderate to severe Crohn’s disease who achieved clinical response to upadacitinib induction treatment, a significantly greater proportion treated with either 15 mg or 30 mg of upadacitinib achieved… Read More
